I have one for you: What rates were disclosed by Vertex for the first time in this year's EASL?
The SVR rates in PROVE-3 stratified by cirrhosis status:
Blue: “12+12” arm Green: “24+24” arm Orange: No-ribavirin arm Gray: SoC control arm
In the “12+12” arm (green), there was essentially no difference in SVR between cirrhotic and non-cirrhotic patients. Non-cirrhotic patients did somewhat better in the other three arms; however, across all four arms, the difference between cirrhotic and non-cirrhotic patients was not statsig.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
AI
